NATH BIOGENES (INDIA)
Back to Balance Sheet
|
NATH BIOGENES (INDIA) Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2013 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹365 Cr | ₹262 Cr | ₹216 Cr | ₹194 Cr | ₹98 Cr |
What is the latest Total Current Liabilities ratio of NATH BIOGENES (INDIA) ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹365 Cr |
| Mar2024 | ₹262 Cr |
| Mar2023 | ₹216 Cr |
| Mar2022 | ₹194 Cr |
| Mar2013 | ₹98 Cr |
How is Total Current Liabilities of NATH BIOGENES (INDIA) Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹365 Cr | 39.19 | |
| Mar2024 | ₹262 Cr | 21.26 | |
| Mar2023 | ₹216 Cr | 11.40 | |
| Mar2022 | ₹194 Cr | 98.02 | |
| Mar2013 | ₹98 Cr | - | |
Compare Total Current Liabilities of peers of NATH BIOGENES (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATH BIOGENES (INDIA) | ₹297.4 Cr | 3.8% | -8.3% | -14.1% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹12,796.5 Cr | -1.4% | -9.1% | -27% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹5,106.4 Cr | 4.4% | -5.8% | 10.5% | Stock Analytics | |
| VENKYS (INDIA) | ₹1,895.5 Cr | 0.6% | -8.5% | -21.4% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,102.7 Cr | -6.5% | -14.2% | -26.4% | Stock Analytics | |
| INDO US BIOTECH | ₹272.8 Cr | 16.7% | -3.5% | -40.7% | Stock Analytics | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | 3.8% |
-8.3% |
-14.1% |
| SENSEX | 0.6% |
1.3% |
7% |
You may also like the below Video Courses